{"id":"calcineurin-inhibitors-maintenance","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Hyperlipidemia"}]},"_chembl":{"chemblId":"CHEMBL5760702","moleculeType":null,"molecularWeight":"276.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcineurin inhibitors (such as tacrolimus and cyclosporine) bind to immunophilins and inhibit calcineurin, a serine/threonine phosphatase essential for T-cell receptor signaling. By blocking calcineurin, they prevent dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing the transcription of IL-2 and other pro-inflammatory cytokines. This mechanism makes them effective for maintenance immunosuppression in transplant recipients.","oneSentence":"Calcineurin inhibitors suppress T-cell activation by blocking calcineurin phosphatase, preventing IL-2 production and T-cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:59.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Prevention of graft rejection and graft-versus-host disease"}]},"trialDetails":[{"nctId":"NCT05238155","phase":"","title":"Evaluation of the Impact of Reduced Immunosuppression","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2021-10-19","conditions":"Graft Vs Host Disease","enrollment":100},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT06676696","phase":"PHASE4","title":"Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-22","conditions":"Renal Failure , Chronic, Graft Failure, Graft Rejection","enrollment":202},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT02327403","phase":"PHASE2","title":"Belatacept Conversion in Proteinuric Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-10","conditions":"Proteinuria","enrollment":15},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT02544113","phase":"PHASE2","title":"A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-12","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT04360031","phase":"","title":"The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2020-02-10","conditions":"Kidney Transplant; Complications, Immunosuppression, Transplant Failure","enrollment":100},{"nctId":"NCT01120028","phase":"PHASE2, PHASE3","title":"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-09","conditions":"Kidney Transplantation","enrollment":852},{"nctId":"NCT01655563","phase":"PHASE2","title":"Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2011-09","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":75},{"nctId":"NCT00135694","phase":"PHASE2","title":"Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure","enrollment":275},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT02134899","phase":"PHASE3","title":"The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10-14","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":3},{"nctId":"NCT01150097","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-31","conditions":"Liver Transplant Recipient","enrollment":284},{"nctId":"NCT03596970","phase":"PHASE3","title":"Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT01636466","phase":"PHASE3","title":"The Everolimus-Transplant Exit Strategy Trial (E-TEST)","status":"TERMINATED","sponsor":"Ashtar Chami","startDate":"2013-06","conditions":"Kidney Failure, Chronic","enrollment":1},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT00284947","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-01","conditions":"Kidney Transplantation, Adverse Effects","enrollment":7},{"nctId":"NCT00170820","phase":"PHASE4","title":"Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-02","conditions":"Renal Transplantation","enrollment":20},{"nctId":"NCT01269684","phase":"PHASE4","title":"Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT00087581","phase":"PHASE4","title":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Kidney Transplantation","enrollment":720},{"nctId":"NCT00468442","phase":"PHASE2","title":"B-Lymphocyte Immunotherapy in Islet Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-11","conditions":"Type 1 Diabetes Mellitus","enrollment":2},{"nctId":"NCT01046045","phase":"PHASE4","title":"Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-04","conditions":"Chronic Allograft Dysfunction in Renal Transplantation","enrollment":17},{"nctId":"NCT00089947","phase":"PHASE2","title":"A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-06","conditions":"Renal Transplantation, Graft Rejection","enrollment":150},{"nctId":"NCT00117689","phase":"PHASE2","title":"Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-04","conditions":"Liver Dysfunction, Rejection, Transplant, Transplantation, Liver","enrollment":75},{"nctId":"NCT00170846","phase":"PHASE4","title":"ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-02","conditions":"Renal Transplantation","enrollment":394},{"nctId":"NCT02062892","phase":"PHASE4","title":"Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2013-12","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT01346085","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2006-10","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00206076","phase":"PHASE4","title":"Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation","status":"COMPLETED","sponsor":"Albert Einstein Healthcare Network","startDate":"2006-08","conditions":"Liver Disease","enrollment":19},{"nctId":"NCT00622869","phase":"PHASE3","title":"Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":719},{"nctId":"NCT01033500","phase":"NA","title":"Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2010-07","conditions":"Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation","enrollment":""},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00452361","phase":"PHASE4","title":"Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Kidney Transplantation","enrollment":31},{"nctId":"NCT01592253","phase":"NA","title":"Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2012-05","conditions":"Acute Rejection of Renal Transplant","enrollment":50},{"nctId":"NCT00129961","phase":"PHASE4","title":"Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-08","conditions":"Skin Neoplasms, Kidney Transplantation","enrollment":86},{"nctId":"NCT00275535","phase":"PHASE4","title":"The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-04","conditions":"Kidney Diseases","enrollment":165},{"nctId":"NCT01455649","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults","status":"UNKNOWN","sponsor":"Deise de Boni Monteiro de Carvalho","startDate":"2011-11","conditions":"Kidney Transplant, Immunosuppression","enrollment":30},{"nctId":"NCT00890253","phase":"PHASE2","title":"Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation","status":"UNKNOWN","sponsor":"Armin Goralczyk","startDate":"2010-01","conditions":"Liver Transplantation, Chronic Renal Insufficiency","enrollment":29},{"nctId":"NCT00267189","phase":"PHASE3","title":"RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Liver Transplantation","enrollment":145},{"nctId":"NCT00273871","phase":"PHASE3","title":"Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-01","conditions":"Graft Rejection, Kidney Failure, Kidney Transplantation","enrollment":190},{"nctId":"NCT01177566","phase":"PHASE4","title":"Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00118742","phase":"PHASE4","title":"Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":"Liver Transplantation","enrollment":293},{"nctId":"NCT00086346","phase":"PHASE3","title":"Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-12","conditions":"Liver Transplantation","enrollment":607},{"nctId":"NCT01034345","phase":"PHASE2","title":"Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2009-11","conditions":"Liver Transplantation","enrollment":52},{"nctId":"NCT00912678","phase":"PHASE4","title":"Minimizing Immunosuppression in Old for Old Kidney Transplantation","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2002-03","conditions":"Kidney Transplantation","enrollment":90},{"nctId":"NCT00903188","phase":"PHASE4","title":"Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2008-10","conditions":"Renal Transplantation","enrollment":152},{"nctId":"NCT00611494","phase":"PHASE4","title":"Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2008-01","conditions":"Organ Transplantation","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["calcineurin-inhibitors based immunosuppression"],"phase":"phase_3","status":"active","brandName":"Calcineurin inhibitors maintenance","genericName":"Calcineurin inhibitors maintenance","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcineurin inhibitors suppress T-cell activation by blocking calcineurin phosphatase, preventing IL-2 production and T-cell proliferation. Used for Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas), Prevention of graft rejection and graft-versus-host disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}